Celldex Therapeutics, Inc. (CLDX) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Celldex Therapeutics (CLDX) is implementing robotic bio-screening to accelerate antibody discovery, which illustrates the company's EV/EBITDA ratio within a historical context. The development of targeted immunotherapy and partnerships with industry behemoths are driving growth. The creation of barzolvolimab for mast cell treatment paves the way for leadership in the treatment of urticaria. The value of 0.00 determines the current magnitude of the metric.
celldex.com - analytical breakdowns and key metrics (CLDX)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Celldex Therapeutics|CLDX - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Celldex Therapeutics, Inc.|CLDX - Company Cumulative Debt|Debts to Book Capitalization Celldex Corp|CLDX - Company Long-Term Liabilities|Company Short-Term Debts Celldex Therapeutics|Quick Liquidity celldex.com
- business earnings and investment ratios data:
CLDX - Company Net Income|Expected Profit Celldex Therapeutics|CLDX - Price to Earnings Ratio|Forward P/E Multiple Celldex Therapeutics|CLDX - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Celldex Corp|CLDX - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Celldex Therapeutics|CLDX - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months celldex.com|CLDX - Earnings per share increase in current year|Expected earnings per share growth for next year Celldex Therapeutics
Initial company analysis:Celldex CLDX
To filter blue-chip assets, investors utilize EV/EBITDA, which compares the total enterprise value of a business with its operating profit before depreciation, interest, and taxes. This metric allows for an assessment of the real value of Celldex Therapeutics (CLDX) while accounting for debt load, which is critical during the expansion of the drug market and amid high expectations for clinical trials reflected in the EV/EBITDA trend of this corporate behemoth.
Competitors of Celldex Therapeutics (CLDX)
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|auriniapharma.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - Company Value to EBITDA|Dianthus Pharma - EV/EBITDA Multiple|Pharvaris Pharma (PHVS) - Enterprise Value to EBITDA Ratio|ABCL: EV/EBITDA Multiple|Company Value to EBITDA tourmalinebio.com (TRML)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precigen|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PHAR|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nektar (NKTR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization UPB (Upstream Pharma)|EV/EBITDA Multiple ZBIO (Zenas Biopharma Inc)|IMNM: Enterprise Value to Operating Income Before Depreciation|Gossamer Bio - EV/EBITDA Multiple|Company Value to EBITDA KalVista Pharma|SEPN (Septerna Corp) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation PVLA|Enterprise Value to EBITDA Ratio SVRA|RIGL: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio ANAB (AnaptysBio)|Enterprise Value to Operating Income Before Depreciation Ratio ATXS|EV/EBITDA Multiple ENGN (enGene Bio)|Business Value to Operating Income Before Depreciation RAPT|Aerovate - EV/EBITDA Multiple|Company Value to EBITDA aclaristx.com|Kyverna Therapeutics, Inc. (KYTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Tiziana Life Sciences Ltd. - Business Value to Operating Income Before Depreciation|CABA (Cabaletta Bio, Inc) - EV/EBITDA Multiple|EV/EBITDA Multiple Ventyx Biosciences, Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Theratechnologies Inc. (THTX)|AVTX: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ELDN (Eledon Pharmaceuticals, Inc.)|Agenus, Inc. (AGEN) - Company Value to EBITDA|CLYM: Enterprise Value to EBITDA Ratio|ZURA - EV/EBITDA Multiple|ATYR (aTyr Pharma, Inc.) - Enterprise Value to EBITDA Ratio|ADAG: Enterprise Value to Operating Income Before Depreciation Ratio|IMA (ImageneBio) - EV/EBITDA Multiple|Shattuck Therapeutics (STTK) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple EQ|Enterprise Value to EBITDA Ratio connectbiopharm.com CNTB|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Immunic IMUX|Total Company Value to Operating Income Before Depreciation Ratio Atara Biotherapeutics, Inc. (ATRA)|InflaRx GmbH - EV/EBITDA Multiple|X4 Pharmaceuticals Inc. (XFOR) - Enterprise Value to EBITDA Ratio|adicetbio.com (ACET) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CELU (Celularity) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|INMB (INmune Bio, Inc.) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation BRNS (barinthusbio.com)|Enterprise Value to EBITDA Ratio KZR (Kezar Life Sciences, Inc.)|SAB Biotherapeutics Inc. - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Akari Therapeutics plc AKTX|ENLV (Enlivex Therapeutics Ltd) - Company Value to Operating Income Before Depreciation Ratio|Q32 Bio Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation GOVX (geovax.com)|EDSA: EV/EBITDA Multiple|iBio Inc (IBIO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Carisma Therapeutics Inc|XTLB: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bolt Biotherapeutics (BOLT)|Enterprise Value to EBITDA Ratio hcwbiologics.com HCWB|EV/EBITDA Multiple APVO (Aptevo Therapeutics Inc.)|EV/EBITDA Multiple aimimmuno.com AIM|ADTX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation GRI (GRI Bio Corporation)|XRTX: EV/EBITDA Multiple|HIND - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Revelation Biosciences, Inc.|Enterprise Value to EBITDA Ratio Indaptus Therapeutics Inc (INDP)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Scinai (SCNI)|Enterprise Value to EBITDA Ratio calcimedica.com CALI|Affimed N.V. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Allakos Inc ALLK|HOOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IGMS (IGM Biosciences, Inc.) - Enterprise Value to Operating Income Before Depreciation|ITOS: EV/EBITDA Multiple|Company Value to EBITDA Ocean Biomedical Corp (OCEA)|TCBP (TC Biopharm) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio thirdharmonicbio.com (THRD)
